{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:06:26Z","timestamp":1789009586076,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10620-026-10057-x","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T19:14:34Z","timestamp":1781810074000},"page":"5127-5136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Incidence of Cirrhosis in Fibrotic Metabolic Dysfunction-Associated Steatohepatitis: A Meta-Analysis of Placebo Arms from Randomized Clinical Trials"],"prefix":"10.1007","volume":"71","author":[{"given":"Samira Mohamad","family":"Khalil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna","family":"Al-Sharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivanna","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matheus","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"10057_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41572-025-00599-1","volume":"11","author":"DQ Huang","year":"2025","unstructured":"Huang DQ, Wong VWS, Rinella ME et al. Metabolic dysfunction-associated steatotic liver disease in adults. Nat Rev Dis Primers. 2025;11:14. https:\/\/doi.org\/10.1038\/s41572-025-00599-1.","journal-title":"Nat Rev Dis Primers."},{"key":"10057_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70001","author":"EKJ Tham","year":"2025","unstructured":"Tham EKJ, Tan DJH, Danpanichkul P et al. The global burden of cirrhosis and other chronic liver diseases in 2021. Liver Int. 2025. https:\/\/doi.org\/10.1111\/liv.70001.","journal-title":"Liver Int."},{"key":"10057_CR3","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/S41591-023-02242-6","volume":"29","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Allen AM, Dubourg J, Noureddin M, Alkhouri N. Challenges and opportunities in NASH drug development. Nat Med. 2023;29:562\u2013573. https:\/\/doi.org\/10.1038\/S41591-023-02242-6.","journal-title":"Nat Med."},{"key":"10057_CR4","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1097\/HEP.0000000000001254","volume":"82","author":"M Souza","year":"2025","unstructured":"Souza M, Al-Sharif L, Antunes VLJ, Huang DQ, Loomba R. Comparison of pharmacological therapies in metabolic dysfunction\u2013associated steatohepatitis for fibrosis regression and MASH resolution: systematic review and network meta-analysis. Hepatology. 2025;82:1523\u20131533. https:\/\/doi.org\/10.1097\/HEP.0000000000001254.","journal-title":"Hepatology."},{"key":"10057_CR5","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/hep.30664","volume":"70","author":"AJ Sanyal","year":"2019","unstructured":"Sanyal AJ, Harrison SA, Ratziu V et al. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials. Hepatology. 2019;70:1913\u20131927. https:\/\/doi.org\/10.1002\/hep.30664.","journal-title":"Hepatology."},{"key":"10057_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/goaf037","author":"D Ko","year":"2025","unstructured":"Ko D, Kim DH, Danpanichkul P et al. Liver cirrhosis in metabolic dysfunction-associated steatohepatitis. Gastroenterol Rep (Oxf). 2025. https:\/\/doi.org\/10.1093\/gastro\/goaf037.","journal-title":"Gastroenterol Rep (Oxf)."},{"key":"10057_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-337374","author":"CT Wu","year":"2026","unstructured":"Wu CT, Targher G, Byrne CD et al. Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement. Gut. 2026. https:\/\/doi.org\/10.1136\/gutjnl-2025-337374.","journal-title":"Gut."},{"key":"10057_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2025.09.035","author":"F Idalsoaga","year":"2025","unstructured":"Idalsoaga F, D\u00edaz LA, Alghsoon S et al. Placebo rates in metabolic dysfunction-associated steatohepatitis clinical trials: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.cgh.2025.09.035.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10057_CR9","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.cgh.2022.07.033","volume":"21","author":"P Le","year":"2023","unstructured":"Le P, Payne JY, Zhang L et al. Disease state transition probabilities across the spectrum of NAFLD: a systematic review and meta-analysis of paired biopsy or imaging studies. Clin Gastroenterol Hepatol. 2023;21:1154\u20131168. https:\/\/doi.org\/10.1016\/j.cgh.2022.07.033.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10057_CR10","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1002\/HEP.32315","volume":"75","author":"CH Ng","year":"2022","unstructured":"Ng CH, Xiao J, Lim WH et al. Placebo effect on progression and regression in NASH: evidence from a meta-analysis. Hepatology. 2022;75:1647\u20131661. https:\/\/doi.org\/10.1002\/HEP.32315.","journal-title":"Hepatology."},{"key":"10057_CR11","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.cgh.2008.07.013","volume":"6","author":"R Loomba","year":"2008","unstructured":"Loomba R, Wesley R, Pucino F, Liang TJ, Kleiner DE, Lavine JE. Placebo in nonalcoholic steatohepatitis: insight into natural history and implications for future clinical trials. Clin Gastroenterol Hepatol. 2008;6:1243\u20131248. https:\/\/doi.org\/10.1016\/j.cgh.2008.07.013.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10057_CR12","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.cgh.2018.06.011","volume":"17","author":"MAT Han","year":"2019","unstructured":"Han MAT, Altayar O, Hamdeh S et al. Rates of and factors associated with placebo response in trials of pharmacotherapies for nonalcoholic steatohepatitis: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17:616-629.e26. https:\/\/doi.org\/10.1016\/j.cgh.2018.06.011.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10057_CR13","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jhep.2009.03.019","volume":"51","author":"CK Argo","year":"2009","unstructured":"Argo CK, Northup PG, Al-Osaimi AMS, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol. 2009;51:371\u2013379. https:\/\/doi.org\/10.1016\/j.jhep.2009.03.019.","journal-title":"J Hepatol."},{"key":"10057_CR14","doi-asserted-by":"publisher","first-page":"e564","DOI":"10.1016\/j.cgh.2021.05.059","volume":"20","author":"IA Rowe","year":"2022","unstructured":"Rowe IA, Parker R. The placebo response in randomized trials in nonalcoholic steatohepatitis simply explained. Clin Gastroenterol Hepatol. 2022;20:e564\u2013e572. https:\/\/doi.org\/10.1016\/j.cgh.2021.05.059.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10057_CR15","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/liv.14749","volume":"41","author":"A Roskilly","year":"2021","unstructured":"Roskilly A, Hicks A, Taylor EJ, Jones R, Parker R, Rowe IA. Fibrosis progression rate in a systematic review of placebo-treated nonalcoholic steatohepatitis. Liver Int. 2021;41:982\u2013995. https:\/\/doi.org\/10.1111\/liv.14749.","journal-title":"Liver Int."},{"key":"10057_CR16","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1016\/j.numecd.2022.07.001","volume":"32","author":"G Pennisi","year":"2022","unstructured":"Pennisi G, Celsa C, Enea M et al. Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis. Nutr Metab Cardiovasc Dis. 2022;32:2279\u20132288. https:\/\/doi.org\/10.1016\/j.numecd.2022.07.001.","journal-title":"Nutr Metab Cardiovasc Dis."},{"key":"10057_CR17","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/BMJ.N71","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, The PRISMA et al. statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021:372. https:\/\/doi.org\/10.1136\/BMJ.N71.","journal-title":"BMJ."},{"key":"10057_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70029","author":"M Souza","year":"2025","unstructured":"Souza M, Al-Sharif L, Diaz I et al. Representation of sex, race and ethnicity in mash randomised controlled trials: a systematic review and meta-analysis. Liver Int. 2025. https:\/\/doi.org\/10.1111\/liv.70029.","journal-title":"Liver Int."},{"key":"10057_CR19","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1053\/J.GASTRO.2018.07.006","volume":"155","author":"SA Harrison","year":"2018","unstructured":"Harrison SA, Abdelmalek MF, Caldwell S et al. simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis. Gastroenterology. 2018;155:1140\u20131153. https:\/\/doi.org\/10.1053\/J.GASTRO.2018.07.006.","journal-title":"Gastroenterology."},{"key":"10057_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.L4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019. https:\/\/doi.org\/10.1136\/BMJ.L4898.","journal-title":"BMJ."},{"key":"10057_CR21","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri BA, Loomba R, Sanyal AJ et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956\u2013965. https:\/\/doi.org\/10.1016\/S0140-6736(14)61933-4.","journal-title":"Lancet."},{"key":"10057_CR22","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679\u2013690. https:\/\/doi.org\/10.1016\/S0140-6736(15)00803-X.","journal-title":"Lancet."},{"key":"10057_CR23","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/J.CGH.2017.04.016","volume":"15","author":"C WahKheong","year":"2017","unstructured":"WahKheong C, Nik Mustapha NR, Mahadeva S. A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2017;15:1940-1949.e8. https:\/\/doi.org\/10.1016\/J.CGH.2017.04.016.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10057_CR24","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1002\/HEP.29477","volume":"67","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Ratziu V, Harrison SA et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology. 2018;67:1754\u20131767. https:\/\/doi.org\/10.1002\/HEP.29477.","journal-title":"Hepatology."},{"key":"10057_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/J.JHEP.2020.02.027","volume":"73","author":"SA Harrison","year":"2020","unstructured":"Harrison SA, Wong VWS, Okanoue T et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials. J Hepatol. 2020;73:26\u201339. https:\/\/doi.org\/10.1016\/J.JHEP.2020.02.027.","journal-title":"J Hepatol."},{"key":"10057_CR26","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/HEP.31622","volume":"73","author":"R Loomba","year":"2021","unstructured":"Loomba R, Noureddin M, Kowdley KV et al. Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH. Hepatology. 2021;73:625\u2013643. https:\/\/doi.org\/10.1002\/HEP.31622.","journal-title":"Hepatology."},{"key":"10057_CR27","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMOA2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384:1113\u20131124. https:\/\/doi.org\/10.1056\/NEJMOA2028395.","journal-title":"N Engl J Med."},{"key":"10057_CR28","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/J.CGH.2023.04.011","volume":"22","author":"R Loomba","year":"2024","unstructured":"Loomba R, Sanyal AJ, Nakajima A et al. Pegbelfermin in Patients With nonalcoholic steatohepatitis and stage 3 fibrosis (FALCON 1): a randomized phase 2b study. Clin Gastroenterol Hepatol. 2024;22:102-112.e9. https:\/\/doi.org\/10.1016\/J.CGH.2023.04.011.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10057_CR29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2401943","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMOA2401943.","journal-title":"N Engl J Med."},{"key":"10057_CR30","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/HEP.0000000000000937","volume":"81","author":"G Musso","year":"2025","unstructured":"Musso G, Pinach S, Mariano F et al. Effect of phospholipid curcumin meriva on liver histology and kidney disease in nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled trial. Hepatology. 2025;81:560\u2013575. https:\/\/doi.org\/10.1097\/HEP.0000000000000937.","journal-title":"Hepatology."},{"key":"10057_CR31","doi-asserted-by":"publisher","first-page":"100915","DOI":"10.1016\/j.jhepr.2023.100915","volume":"6","author":"C Akbari","year":"2024","unstructured":"Akbari C, Dodd M, St\u00e5l P et al. Long-term major adverse liver outcomes in 1,260 patients with non-cirrhotic NAFLD. JHEP Reports. 2024;6:100915. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100915.","journal-title":"JHEP Reports."},{"key":"10057_CR32","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1002\/hep.30946","volume":"70","author":"R Loomba","year":"2019","unstructured":"Loomba R, Adams LA. The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH. Hepatology. 2019;70:1885\u20131888. https:\/\/doi.org\/10.1002\/hep.30946.","journal-title":"Hepatology."},{"key":"10057_CR33","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. New Engl J Med. 2025;392:2089\u20132099. https:\/\/doi.org\/10.1056\/NEJMoa2413258.","journal-title":"New Engl J Med."},{"key":"10057_CR34","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMOA2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497\u2013509. https:\/\/doi.org\/10.1056\/NEJMOA2309000.","journal-title":"N Engl J Med."},{"key":"10057_CR35","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/apt.70565","volume":"63","author":"M Souza","year":"2026","unstructured":"Souza M, Al-Sharif L, Antunes VLJ, Wong SY, Huang DQ, Loomba R. Network meta-analysis: comparison of pharmacological therapies in compensated metabolic dysfunction-associated steatohepatitis cirrhosis for fibrosis regression and MASH resolution. Aliment Pharmacol Ther. 2026;63:922\u2013931. https:\/\/doi.org\/10.1111\/apt.70565.","journal-title":"Aliment Pharmacol Ther."},{"key":"10057_CR36","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1111\/apt.70516","volume":"63","author":"V Ajmera","year":"2026","unstructured":"Ajmera V, Vuppalanchi R, Khalili M et al. Clinical trial: semaglutide versus placebo in NIT-assessed MASH \u2014a multicenter randomised placebo-controlled trial (SAMARA). Aliment Pharmacol Ther. 2026;63:1080\u20131088. https:\/\/doi.org\/10.1111\/apt.70516.","journal-title":"Aliment Pharmacol Ther."},{"key":"10057_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/J.JHEPR.2025.101351","author":"J Fichez","year":"2025","unstructured":"Fichez J, Mouillot T, Vonghia L et al. Non-invasive tests for fibrotic MASH for reducing screen failure in therapeutic trials. JHEP Rep. 2025. https:\/\/doi.org\/10.1016\/J.JHEPR.2025.101351.","journal-title":"JHEP Rep."},{"key":"10057_CR38","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/apt.18498","volume":"61","author":"M Souza","year":"2025","unstructured":"Souza M, Amaral MJM, Lima LCV, Villela-Nogueira CA. Meta-analysis of placebo-treated patients: dropout rates from treatment in MASH randomised controlled trials. Aliment Pharmacol Ther. 2025;61:776\u2013786. https:\/\/doi.org\/10.1111\/apt.18498.","journal-title":"Aliment Pharmacol Ther."},{"key":"10057_CR39","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.14309\/ajg.0000000000003520","volume":"120","author":"M Souza","year":"2025","unstructured":"Souza M, Al-Sharif L, Diaz I, Khalil SM. Enrollment in metabolic dysfunction-associated steatohepatitis clinical trials: a pooled analysis of screen failure rates. Am J Gastroenterol. 2025;120:2709\u20132713. https:\/\/doi.org\/10.14309\/ajg.0000000000003520.","journal-title":"Am J Gastroenterol."},{"key":"10057_CR40","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.cgh.2025.02.035","volume":"24","author":"JT Grady","year":"2026","unstructured":"Grady JT, Cyrus JW, Sterling RK. Novel noninvasive tests for liver fibrosis: moving beyond simple tests in metabolic dysfunction-associated steatotic liver disease. Clin Gastroenterol Hepatol. 2026;24:342-354.e2. https:\/\/doi.org\/10.1016\/j.cgh.2025.02.035.","journal-title":"Clin Gastroenterol Hepatol."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-10057-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-10057-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-10057-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:18:27Z","timestamp":1789006707000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-10057-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10057"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-10057-x","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}